Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A post-marketing clinical study to evaluate the efficacy and safety of pertuzumab combined with trastuzumab and docetaxel as first line treatment in HER2- positive inoperable or recurrent breast cancer

Next Previous
Trial Profile

A post-marketing clinical study to evaluate the efficacy and safety of pertuzumab combined with trastuzumab and docetaxel as first line treatment in HER2- positive inoperable or recurrent breast cancer

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 07 Dec 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Docetaxel (Primary) ; Pertuzumab (Primary) ; Trastuzumab (Primary)
  • Indications Advanced breast cancer; HER2 positive breast cancer
  • Focus Therapeutic Use
  • Acronyms COMACHI
  • Sponsors Chugai Pharmaceutical

Most Recent Events

  • 17 Aug 2017 Planned End Date changed from 1 Aug 2017 to 1 Mar 2019.
  • 10 Jun 2016 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top